Prosecution Insights
Last updated: November 18, 2026
Application No. 18/561,451

ADJUSTABLE SELF-ANCHORING CATHETERS AND METHODS OF USE

Non-Final OA §101§103
Filed
Nov 16, 2023
Priority
Jun 03, 2021 — provisional 63/196,354 +2 more
Examiner
THOMAN, EVELYN ANNE
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Pavmed Inc.
OA Round
1 (Non-Final)
100%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 100% — above average
100%
Career Allowance Rate
1 granted / 1 resolved
+30.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
32 currently pending
Career history
39
Total Applications
across all art units

Office Action

§101 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election with traverse of Group I: Claims 1-21, drawn to a self-anchoring catheter in combination with Species 1A: Figs. 1A-1C in the reply filed on 07/20/2026 is acknowledged. The traversal is on the grounds that “the groups are not patentably distinct and searching them together presents no undue burden to the examiner”, as well as “a proper search directed to the novel aspects of Group I will inherently encompass the subject matter of” Group II. This is not found persuasive because there would need to be different search queries to find both how a self-anchoring catheter is to look and a process for operating a self-anchoring catheter. Although both groups discuss self-anchoring catheters, there exists different areas of search for operating catheters and details of catheters. In the Requirement for Restriction/Election, the examiner provided a proper distinction of the special technical features between Groups I and II, specifically noting the specific steps of the method of Group II not needed by Group I. Therefore, the arguments are not convincing. The requirement is still deemed proper and is therefore made FINAL. In Applicant’s Remarks to the Restriction/Election Requirement, the applicant states that “[t]he claims readable on the elected species are claims 1, and 3-21”. The examiner disagrees, as Figs. 1A-1C do not include information or visual representation regarding the anchor portion as a stiffened member, the body having shape memory capability, or the catheter including a transitioning member. Therefore, claims 7-9, 17-19, and 21 have been withdrawn by the examiner for being directed to an unelected species. Thus, claims 1, 3-4, 6, 11, and 14-16 remain pending in the application. Information Disclosure Statement The information disclosure statement (IDS) submitted on 03/05/2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Objections Claim 16 is objected to because of the following informalities: At the end of the claim, the claim uses the language “in at least on configuration”. This language leaves the limitation of the claim open to interpretation, and may insinuate multiple embodiments. The examiner suggests removing the language and/or modifying the claim to more clearly state that at some point during device use, the enclosure may at least partially receive the anchor portion. Appropriate correction is required. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Section 33(a) of the America Invents Act reads as follows: Notwithstanding any other provision of law, no patent may issue on a claim directed to or encompassing a human organism. Claims 1 and 14 are rejected under 35 U.S.C. 101 and section 33(a) of the America Invents Act as being directed to or encompassing a human organism. See also Animals - Patentability, 1077 Off. Gaz. Pat. Office 24 (April 21, 1987) (indicating that human organisms are excluded from the scope of patentable subject matter under 35 U.S.C. 101). Claim 1, in line 4, positively recites “an anchor portion imparted on the body to secure the body to surrounding tissue”. Claim 14, in lines 2-3, positively recites “such that the anchor portion creates a traction force within surrounding tissue”. Therefore, the claims appear to positively recite “tissue” which are directed to a human organism and thus rejected under 35 U.S.C. 101. To overcome the rejection, the applicant could adopt the following language: For claim 1, “an anchor portion imparted on the body configured to secure the body to surrounding tissue”. For claim 14, “such that the anchor portion is configured to create within surrounding tissue”. Due to claim dependency from claims 1 and 14, claims 3-4, 6, 11, and 15-16 are subsequently rejected. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 3-4, 6, 11, and 14-16 are rejected under 35 U.S.C. 103 as being unpatentable over Aklong et al. (United States Patent Application Publication No. US 2016/0151608 A1; herein, Aklong), and further in view of Piskun (United States Patent Application Publication No. US 2016/0374658 A1). Regarding claim 1, Aklong discloses a self-anchoring catheter (catheter 100) comprising: a body (catheter section 104) having a proximal end (proximal catheter section 116) and a distal end (distal end 112), and defining a pathway therebetween (pathway 108), the body being axially rigid ([0033], “the catheter section 104 may be constructed to be rigid”); an anchor portion (jacket 122 at anchoring section 106) imparted on the body (FIG. 1D-1E) to secure the body to surrounding tissue ([0034], “an anchoring section 106 designed to secure the catheter 100 onto a tissue”); and Aklong includes a hub 102 located adjacent to the proximal end of the body, as seen in FIG. 1A. Yet Aklong does not explicitly disclose an actuator disposed adjacent the proximal end of the body to positionally control movement of the anchor portion and its position relative to the actuator. However, Piskun teaches an actuator (FIG. 6A-6D, retractor actuator 614) disposed adjacent the proximal end of the body (FIG. 6A-6D) to positionally control movement of the anchor portion and its position relative to the actuator ([0159], [0161], retractor actuator 614 has the ability to reversibly expand the retractor 650). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the catheter disclosed by Aklong to include an actuator to positionally control movement of the anchor portion and its position relative to the actuator as taught by Piskun in order to control distal movement of the anchor portion ([0161]). Regarding claim 3, in the modified catheter of Aklong, Aklong discloses the anchor portion is a jacket (jacket 122) configured to receive at least a portion of the body (FIG. 1D-1E). Regarding claim 4, in the modified catheter of Aklong, Aklong discloses the jacket includes a helical portion that forms an anchoring section with at least one turn ([0035], FIG. 1D-1E, “a jacket 122 with a helical shape can be applied to the anchoring portion 106 of the catheter to render the anchoring portion 106 more rigid and also shape the anchoring section 106 into a helical configuration”). Regarding claim 6, in the modified catheter of Aklong, Aklong discloses the jacket is configured to reshape a section of the body that is disposed therein ([0035], FIG. 1D-1E, jacket 122 shapes the anchoring section 106). Regarding claim 11, in the modified catheter of Aklong, Aklong does not explicitly disclose the actuator includes a control interface configured to actuate movement of the anchor portion. However, Piskun teaches the actuator includes a control interface (FIG. 6A-6D, retractor actuator 614) configured to actuate movement of the anchor portion ([0159], [0161], retractor actuator 614 has the ability to reversibly expand the retractor 650 and retractor components). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the catheter disclosed by modified Aklong to include a control interface to actuate movement of the anchor portion as taught by Piskun in order to control distal movement of the anchor portion ([0161]). Regarding claim 14, in the modified catheter of Aklong, Aklong discloses the anchor portion includes a plurality of turns at a predefined pitch such that the anchor portion creates a traction force within surrounding tissue ([0035], “This helical structure can include a plurality of turns spaced apart at certain pitch designed to create a traction force with surrounding tissue.”). Regarding claim 15, in the modified catheter of Aklong, Aklong discloses the plurality of turns includes helical turns configured to receive the surrounding tissue ([0035], “The anchoring section 106 as shown in FIG. 1 effectively allows tissues to be lodged between each turns of the helical portion, thereby optimizing the traction force between the catheter 100 with the surrounding tissues.”, When the catheter 100 is inserted into a tissue, the anchoring section 106 pushes against and receives the surrounding tissue in order to secure itself.). Regarding claim 16, in the modified catheter of Aklong, Aklong does disclose a hub 102 which may be designed to connect to a wide variety of instruments. Yet Aklong does not explicitly disclose the actuator includes an enclosure which at least partially receives the anchor portion in at least one configuration. However, Piskun teaches the actuator includes an enclosure which at least partially receives the anchor portion in at least one configuration (FIG. 6A-6D, [0161], Retractor actuator 614 is positioned on the handle 680 and is connected to components of the retractor 650, specifically retractor elements 651,652. FIG. 6B shows retractor elements 651,652 enclosed within housing 680 before moving distally in FIG. 6D. The examiner interprets this as the housing partially receiving the retractor 650.). Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the catheter disclosed by modified Aklong to include an enclosure which at least partially receives the anchor portion as taught by Piskun in order to protect and control expansion of the anchor portion ([0165]). Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Osbourne (United States Patent Application Publication No. US 2001/0053890 A1) is considered relevant prior art with regards to an insertion catheter with a coiled portion. Sing et al. (United States Patent Application Publication No. US 2011/0230700 A1) is considered relevant prior art with regards to movable helical catheters attached out a control apparatus. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Evelyn A Thoman whose telephone number is (571)272-8496. The examiner can normally be reached Monday-Friday 8:00 a.m-4:30 p.m.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Tsai can be reached at 571-270-5246. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /EVELYN A THOMAN/Patent Examiner, Art Unit 3783 /THEODORE J STIGELL/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Nov 16, 2023
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §101, §103 (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
100%
Grant Probability
99%
With Interview (+0.0%)
Low
PTA Risk
Based on 1 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month